Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Janssen, a unit of Johnson & Johnson (J&J), has recalled 70,000 syringes of its antipsychotic drug Invega Sustenna from the market.
Subscribe to our email newsletter
The move came after Janssen found cracks in some of the pre-filled 234-milligram-strength injections which could affect the drug’s sterility, Bloomberg.com reported.
The label on the syringe entirely covers the crack and so, it goes undetected by the user.
In a letter posted on its website, Janssen said that there have been no reports of adverse effects, infection, or leakage associated with cracked syringe barrels since the launch of the product.
No other strengths of the drug or products marketed by the company are affected, Janssen said.
Invega is indicated for the treatment of schizophrenia and was approved in December 2006.
It is related to Risperdal, a former blockbuster antipsychotic that lost patent protection in 2008.
Janssen markets Invega in the US for Johnson &Johnson, and expects to resume shipping it in early March and return to normal levels of product availability in April, the news agency reported.